Project description
Nasal vaccines against key respiratory pathogens
Vaccines targeting respiratory bacteria and viruses are often administered by intramuscular or subcutaneous injection. However, this vaccination route seems often ineffective with limited impact on pathogen transmission. The EU-funded NOSEVAC project brings together a large team of experts to pioneer nasal vaccines that block early infection stages and inhibit colonisation of the upper respiratory tract. The consortium will develop both RNA and protein-based vaccines against key pathogens such as COVID-19, influenza and S. pneumoniae and test their efficacy. Moreover, NOSEVAC will advance our understanding of respiratory tract infection, and will inform rational development of nasal vaccines against respiratory pathogens.
Objective
Bacterial and viral respiratory infections are a leading cause of morbidity and mortality worldwide. Streptococcus pneumoniae and Bordetella bacteria, influenza virus and SARS-CoV-2, are responsible for diseases with major public health impact: community-acquired pneumonia, whooping cough, influenza and COVID-19, respectively. Vaccines against some of these diseases, administered by intramuscular or subcutaneous injection, do not prevent colonization or infection of the upper respiratory tract (URT), and therefore have limited impact on pathogen transmission.
The NOSEVAC consortium aims to develop and assess innovative nasal vaccine platforms as a novel concept to block the earliest stage of infection, thereby inhibiting URT colonisation, transmission and disease. The project builds on a unique consortium of 12 renowned and complementary teams from the EU, UK and Switzerland.
NOSEVAC’s objectives are to:
• Develop vaccine formulations for nasal delivery of RNA- and protein-based antigens
• Discover bacterial antigens that promote colonization of the URT
• Use a combination of in vitro and in vivo models for optimal evaluation of vaccines efficacy
• Identify key host immune factors required for long-term protection of the URT in human
• Deliver two nasal vaccine candidates to fight S. pneumoniae and Bordetella infection, and a single bivalent vaccine to prevent influenza and COVID-19
• Address acceptability of nasal vaccination
Expected outcomes include (1) strengthening innovation in Europe by enriching the pipeline for novel vaccines against (new) respiratory infections, (2) increasing knowledge on the mechanisms underlying URT colonization, infection and immunity, and (3) evaluating nasal vaccine acceptability by stakeholders. NOSEVAC will develop strategic research avenues to fight respiratory pathogens including those with epidemic potential and will facilitate evidence-based decision making to policy makers and investors.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine pneumology
- medical and health sciences health sciences public health
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences infectious diseases RNA viruses coronaviruses
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.2.1 - Health
MAIN PROGRAMME
See all projects funded under this programme -
HORIZON.2.1.4 - Infectious Diseases, including poverty-related and neglected diseases
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-RIA - HORIZON Research and Innovation Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-HLTH-2022-DISEASE-06-two-stage
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
69120 Heidelberg
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.